C-EMZSVandria
small molecules, mitophagy, mitochondrial function
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EMZS
C-EMZSC-EMZSsmall molecules, mitophagy, mitochondrial function
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Vandria small molecules, mitophagy, mitochondrial function
Vandria is a clinical-stage biotech company developing first-in-class small molecules against a novel target to restore mitochondrial function and reduce inflammation. Its lead CNS asset, VNA-318, is an orally bioavailable, brain-penetrant molecule with a dual mode of action intended to improve cognition and provide longer-term disease-modifying effects. The company also has small-molecule programs for age-related and chronic diseases of the muscle, lung and liver.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Vandria — Translational · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic